替加环素联合头孢哌酮-舒巴坦治疗广泛耐药鲍曼不动杆菌医院获得性肺炎临床疗效观察

发布时间：2018-04-30 23:34

本文选题：头孢哌酮-舒巴坦 + 替加环素　；参考：《中国感染与化疗杂志》2015年05期

【摘要】：目的观察替加环素联合头孢哌酮-舒巴坦对广泛耐药鲍曼不动杆菌医院获得性肺炎的临床疗效。方法对东莞市第三人民医院的53例广泛耐药鲍曼不动杆菌医院获得性肺炎患者随机分为试验组(27例)和对照组(26例)。试验组给予替加环素联合头孢哌酮-舒巴坦抗感染治疗,对照组单用替加环素,两组疗程均为14 d。结果治疗结束后,试验组有效率70.4%(19/27),明显高于对照组的38.5%(10/26)(P0.05),但两组细菌清除率差异无统计学意义(55.6%对38.5%,P0.05);两组不良反应的发生率差异也无统计学意义(14.3%对15.4%,P0.05)。结论大剂量的头孢哌酮-舒巴坦可提高替加环素对广泛耐药鲍曼不动杆菌医院获得性肺炎的临床疗效,为临床治疗该类菌株感染提供了一种新的治疗策略。
[Abstract]:Objective To observe the clinical efficacy of tegacycline combined with cefoperazone and sulbactam in the treatment of nosocomial pneumonia with extensively drug-resistant Acinetobacter Bauman. Methods 53 patients with acquired pneumonia in third people's Hospital in Dongguan were randomly divided into an experimental group (27 cases) and a control group (26 cases). The test group was given tegacycline. Combined with cefoperazone and sulbactam for anti infection treatment, the control group only used tegengin, the two groups were 14 d. treatment end, the effective rate of the test group was 70.4% (19/27), significantly higher than the control group 38.5% (10/26) (P0.05), but the two groups of bacterial clearance difference was not statistically significant (55.6% to 38.5%, P0.05); two groups of adverse reaction rates difference There is no statistical significance (14.3% to 15.4%, P0.05). Conclusion the large dose of cefoperazone sulbactam can improve the clinical efficacy of tegoperazine in the hospital acquired pneumonia of Acinetobacter Bauman, and provide a new therapeutic strategy for the clinical treatment of this type of infection.

【作者单位】：东莞市第三人民医院药学部;东莞市第三人民医院呼吸内科;华中科技大学同济医学院附属同济医院药学部;
【分类号】：R563.1

【参考文献】